Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DVAX Dynavax

Market Closed 12-12 16:00:00 EST

10.80

-0.06

-0.55%

盘后10.80

+0.000.00%

16:10 EST

High10.91	Low10.76	Vol1.07M
Open10.89	D1 Closing10.86	Amplitude1.38%
Mkt Cap1.27B	Tradable Cap1.07B	Total Shares117.42M
T/O11.55M	T/O Rate1.08%	Tradable Shares98.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DVAX","market":"US","secType":"STK","nameCN":"Dynavax","latestPrice":10.8,"timestamp":1765573200000,"preClose":10.86,"halted":0,"volume":1066655,"hourTrading":{"tag":"盘后","latestPrice":10.8,"preClose":10.8,"latestTime":"16:10 EST","volume":24913,"amount":269059.1,"timestamp":1765573803943},"delay":0,"floatShares":98912259,"shares":117424968,"eps":-0.359451,"marketStatus":"Market Closed","change":-0.06,"latestTime":"12-12 16:00:00 EST","open":10.89,"high":10.91,"low":10.7605,"amount":11545359.522531,"amplitude":0.013766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.359451,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1077166800000,"exchange":"NASDAQ","adjPreClose":10.86,"preHourTrading":{"tag":"盘前","latestPrice":10.7,"preClose":10.86,"latestTime":"09:29 EST","volume":2,"amount":21.06,"timestamp":1765549797206},"postHourTrading":{"tag":"盘后","latestPrice":10.8,"preClose":10.8,"latestTime":"16:10 EST","volume":24913,"amount":269059.1,"timestamp":1765573803943},"volumeRatio":0.7332837994305742,"impliedVol":0.5082,"impliedVolPercentile":0.844},"requestUrl":"/m/hq/s/DVAX","defaultTab":"news","newsList":[{"id":"2588772529","title":"Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772529","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772529?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:35","pubTimestamp":1764610500,"startTime":"0","endTime":"0","summary":"Vinay Prasad, a top regulator at the FDA, did not detail the data in the internal memo that led to the conclusion. Pfizer and BioNTech developed the COVID-19 vaccine Comirnaty.Shares of Moderna and BioNTech were down on Monday morning, likely in response to a FDA official's memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children.Concern about that link, particularly relating to teenage boys and young men, has been a key argument against administering mRNA-based COVID vaccines in children.Vinay Prasad, the head of the Food and Drug Administration's Center for Biologics Evaluation and Research, reportedly issued a memo to staff last week that said the regulator plans to acknowledge that 10 children died after getting the vaccine. . The FDA has not publicly shared the internal research cited in the memo, although Prasad said it comes from the Vaccine Adverse Event Reporting System, which gathers reports of adverse events from the public, healthcare profe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LINK.USD.HKCC","IE00BBT3K403.USD","SG9999003800.SGD","LU1894683348.USD","MRNA","BK4585","BK4581","SG9999011175.SGD","LU1894683264.USD","LU0225284248.USD","BK4535","LU0058720904.USD","LU0170899867.USD","LU1883839398.USD","BK4532","LU0234572021.USD","LU0225771236.USD","BK4551","BK4139","BK4592","LU0985481810.HKD","VXRT","LU0122379950.USD","IE00BLSP4452.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","LU0456855351.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0053671581.USD","BK4534","LU0321505439.SGD","SG9999013999.USD","LU1066051498.USD","DVAX","BK4568","BK4599","BNTX","SG9999001176.SGD","BK4533","SG9999001176.USD","LU1066053197.SGD","SGXZ57979304.SGD","LU0306806265.USD","IE00BLSP4239.USD","PCVX"],"gpt_icon":1},{"id":"2586427218","title":"Exploring 3 High Growth Tech Stocks in the US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2586427218","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586427218?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:08","pubTimestamp":1764068888,"startTime":"0","endTime":"0","summary":"As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those related to artificial intelligence. In this environment of heightened market activity and shifting economic indicators, identifying high-growth tech stocks requires a keen understanding of innovation trends and the ability to navigate volatility effectively.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","CTV.AU","DVAX","VRDN","CTV","BK4009","BK4139","BK7045","DSP"],"gpt_icon":0},{"id":"2584758469","title":"Dynavax Technologies to Join Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584758469","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584758469?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:01","pubTimestamp":1763586072,"startTime":"0","endTime":"0","summary":"Dynavax Technologies Corporation will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2 at 2:10 p.m. ET. The presentation will be webcast and accessible through the Investors section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire  on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL8lZGgh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","DVAX","EVR","BK4139"],"gpt_icon":0},{"id":"2584626604","title":"Should Dynavax Technologies' (DVAX) $100 Million Buyback and Guidance Update Prompt a Reassessment by Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626604","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626604?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:18","pubTimestamp":1763421514,"startTime":"0","endTime":"0","summary":"Dynavax Technologies Corporation recently announced a US$100 million share repurchase program, reported its third quarter 2025 earnings, and reiterated full-year net product revenue guidance for HEPLISAV-B of US$315 million to US$325 million.\nThis series of updates highlights both management’s ongoing confidence in the core hepatitis B franchise and a renewed emphasis on capital returns to shareholders.\nLet’s explore how the newly announced share repurchase program may influence Dynavax's...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/should-dynavax-technologies-dvax-100-million-buyback-and-gui","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/should-dynavax-technologies-dvax-100-million-buyback-and-gui","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ISBC","DVAX","BK4211"],"gpt_icon":0},{"id":"2582602643","title":"Exploring Dynavax Technologies (DVAX) Valuation Following Q3 Earnings Growth and $100M Buyback Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582602643","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582602643?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:24","pubTimestamp":1762867495,"startTime":"0","endTime":"0","summary":"Dynavax Technologies (DVAX) just released its third-quarter earnings, showing increases in both revenue and net income compared to last year. The company also announced plans for a $100 million share buyback program.\nSee our latest analysis for Dynavax Technologies.\nFollowing the upbeat earnings and buyback announcement, Dynavax Technologies has seen a wave of renewed investor interest in recent weeks. The company’s share price jumped 8% over the past week and is up nearly 11% in the last...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-dynavax-technologies-dvax-valuation-following-q3-e","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-dynavax-technologies-dvax-valuation-following-q3-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DVAX"],"gpt_icon":0},{"id":"2581196320","title":"Dynavax Technologies Up Over 7%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581196320","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581196320?lang=en_us&edition=fundamental","pubTime":"2025-11-07 02:32","pubTimestamp":1762453920,"startTime":"0","endTime":"0","summary":"Dynavax Technologies Corporation  is currently at $11.07, up $0.77 or 7.48%. --Would be highest close since Aug. 6, 2025, when it closed at $11.19. --On pace for largest percent increase since Nov. 8, 2024, when it rose 8.24%. --Currently up two consecutive days; up 10.15% over this period. --Down 13.31% year-to-date; on pace for worst year since 2022, when it fell 24.38%. --Down 88.76% from its all-time closing high of $98.50 on Dec. 11, 2006. --Down 7.90% from 52 weeks ago , when it closed at $12.02. --Down 23.12% from its 52-week closing high of $14.40 on March 7, 2025. --Traded as high as $11.21; highest intraday level since Aug. 21, 2025, when it hit $11.45. --Up 8.83% at today's intraday high; largest intraday percent increase since Aug. 21, 2025, when it rose as much as 9.88%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"2581009785","title":"Evercore ISI Reaffirms Their Buy Rating on Dynavax (DVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009785?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:19","pubTimestamp":1762442349,"startTime":"0","endTime":"0","summary":"In a report released today, Jonathan Miller from Evercore ISI maintained a Buy rating on Dynavax, with a price target of $16.00. Miller covers the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-dynavax-dvax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-dynavax-dvax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DVAX"],"gpt_icon":0},{"id":"2581630340","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dynavax (DVAX) and QuidelOrtho (QDEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581630340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581630340?lang=en_us&edition=fundamental","pubTime":"2025-11-06 18:30","pubTimestamp":1762425042,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dynavax (DVAX – Research Report) and QuidelOrtho (QDEL – Research...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-dynavax-dvax-and-quidelortho-qdel-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-dynavax-dvax-and-quidelortho-qdel-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","QDEL","HCSG","DVAX","BK4588","LU0128526141.USD","XBI","BK4198","LABU","BK4581","BK4585","LU0029874061.USD","BK4137","BK4139","XLV"],"gpt_icon":0},{"id":"2581000083","title":"Vaxart Partners with Dynavax for Oral COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000083","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000083?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:35","pubTimestamp":1762382110,"startTime":"0","endTime":"0","summary":"Vaxart ( ($VXRT) ) has shared an announcement. On November 4, 2025, Vaxart entered into an exclusive license and collaboration agreement with Dynav...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vaxart-partners-with-dynavax-for-oral-covid-19-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vaxart-partners-with-dynavax-for-oral-covid-19-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DVAX","BK4551","BK4568","BK4548","BK4588","BK4139","BNTX","BK4535","BK4585"],"gpt_icon":0},{"id":"2581709443","title":"Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709443","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709443?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:04","pubTimestamp":1762376640,"startTime":"0","endTime":"0","summary":"Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLbFjbFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","VXRT","DVAX"],"gpt_icon":0},{"id":"2581912709","title":"Dynavax Technologies Q3 EPS $0.21 Beats $0.12 Estimate, Sales $94.876M Beat $94.003M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581912709","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581912709?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:02","pubTimestamp":1762376526,"startTime":"0","endTime":"0","summary":"Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.12 by 75 percent. This is a 75 percent increase over earnings of $0.12 per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48669052/dynavax-technologies-q3-eps-0-21-beats-0-12-estimate-sales-94-876m-beat-94-003m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dynavax Technologies Q3 EPS $0.21 Beats $0.12 Estimate, Sales $94.876M Beat $94.003M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX"],"gpt_icon":0},{"id":"2581709958","title":"Vaxart Secures $30 Million From Dynavax for Oral COVID-19 Vaccine License","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709958","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709958?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:00","pubTimestamp":1762376440,"startTime":"0","endTime":"0","summary":"Vaxart Inc. has announced an exclusive license agreement with Dynavax Technologies for its novel oral COVID-19 vaccine program. Under the terms of the agreement, Dynavax will pay Vaxart a $25 million upfront license fee and make a $5 million equity investment. Dynavax will receive an exclusive, worldwide license to develop and commercialize oral COVID-19 vaccines based on Vaxart's delivery platform. Vaxart will retain full operational and financial responsibility for the program through the completion of its ongoing Phase 2b clinical trial and the subsequent End of Phase 2 meeting with the FDA. After the Phase 2b data readout, Dynavax may elect to assume responsibility for future clinical development and commercialization, with Vaxart eligible for additional milestone payments and royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1dMhkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX","VXRT","BK4568"],"gpt_icon":0},{"id":"2581709688","title":"Vaxart Inc - to Receive $25 Mln Upfront and $5 Mln Equity Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709688?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:00","pubTimestamp":1762376400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1CYGFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DVAX","VXRT","BK4568","BK4139"],"gpt_icon":0},{"id":"2581709154","title":"Vaxart Inc - May Receive up to $195 Mln in Regulatory Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709154?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:00","pubTimestamp":1762376400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1CYGFJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DVAX","BK4568","VXRT","BK4139"],"gpt_icon":0},{"id":"2581670954","title":"Vaxart Inc - Dynavax to Pay Additional $50 Mln Fee to Vaxart","url":"https://stock-news.laohu8.com/highlight/detail?id=2581670954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581670954?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:00","pubTimestamp":1762376400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1CYGFJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DVAX","BK4139","BK4568","VXRT"],"gpt_icon":0},{"id":"2581095977","title":"Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral Covid-19 Vaccine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095977?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:00","pubTimestamp":1762376400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA1CYGFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DVAX","BK4139","BK4568","VXRT"],"gpt_icon":0},{"id":"2580476062","title":"How Strong Z-1018 Shingles Vaccine Data at Dynavax Technologies (DVAX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2580476062","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580476062?lang=en_us&edition=fundamental","pubTime":"2025-11-02 01:29","pubTimestamp":1762018188,"startTime":"0","endTime":"0","summary":"Dynavax Technologies recently presented positive topline data from Part 1 of its Phase 1/2 clinical trial of Z-1018, a novel shingles vaccine candidate, and announced the start of Part 2 enrolling adults aged 70 and older.\nThe trial results showed strong immune responses and tolerability for Z-1018 at levels comparable to Shingrix®, highlighting potential for increased competition in the shingles vaccine market.\nWe'll explore how advancement of Z-1018 into head-to-head trials with Shingrix...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/how-strong-z-1018-shingles-vaccine-data-at-dynavax-technolog","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/how-strong-z-1018-shingles-vaccine-data-at-dynavax-technolog","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"2578567968","title":"High Growth Tech Stocks In US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2578567968","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578567968?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:08","pubTimestamp":1761584893,"startTime":"0","endTime":"0","summary":"The U.S. stock market has recently seen major indices like the Dow Jones, S&P 500, and Nasdaq reach new highs, driven by optimism surrounding U.S.-China trade talks and the potential for Federal Reserve interest rate cuts. In this environment of heightened investor enthusiasm for technology stocks, particularly those involved in AI advancements and data center innovations, identifying high growth tech stocks requires a focus on companies that are well-positioned to capitalize on these trends...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/643468691-main-header/1669268249538","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/643468691-main-header/1669268249538"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-vtex/vtex/news/high-growth-tech-stocks-in-us-market","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-vtex/vtex/news/high-growth-tech-stocks-in-us-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DSP","BK4009","DVAX","VTEX","BK7045","CTV","BK4116","BK4023","CTV.AU","BK4539","BK4077","BK4139","BK4549"],"gpt_icon":0},{"id":"2578052700","title":"Dynavax Technologies (DVAX) Is Up 5.7% After Positive Z-1018 Shingles Vaccine Data Release – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578052700","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578052700?lang=en_us&edition=fundamental","pubTime":"2025-10-25 06:37","pubTimestamp":1761345424,"startTime":"0","endTime":"0","summary":"Earlier this week, Dynavax Technologies presented positive topline data from Part 1 of its Phase 1/2 clinical trial evaluating Z-1018, its novel shingles vaccine candidate, showing immune responses and tolerability comparable to Shingrix, and confirmed that enrollment is underway for the head-to-head Part 2 study in adults aged 70 and older.\nThis advancement positions Dynavax to potentially enter the competitive shingles vaccine market, where current immunization options for older adults are...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/dynavax-technologies-dvax-is-up-57-after-positive-z-1018-shi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/dynavax-technologies-dvax-is-up-57-after-positive-z-1018-shi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"2577315461","title":"Dynavax Technologies Corporation to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2577315461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577315461?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:01","pubTimestamp":1761163283,"startTime":"0","endTime":"0","summary":"Dynavax Technologies Corporation will report third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. A conference call and live audio webcast will be held on November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the Events & Presentations page on the \"Investors\" section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via PR Newswire  on October 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL4LZ28p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dynavax.com","stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.0409},{"period":"3month","weight":0.1477},{"period":"6month","weight":0.0516},{"period":"1year","weight":-0.1686},{"period":"ytd","weight":-0.1543}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.002211},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.027901},{"month":3,"riseRate":0.409091,"avgChangeRate":-0.007392},{"month":4,"riseRate":0.318182,"avgChangeRate":-0.006058},{"month":5,"riseRate":0.5,"avgChangeRate":0.022333},{"month":6,"riseRate":0.5,"avgChangeRate":0.023462},{"month":7,"riseRate":0.545455,"avgChangeRate":0.057705},{"month":8,"riseRate":0.454545,"avgChangeRate":0.040776},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.02771},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003182},{"month":11,"riseRate":0.590909,"avgChangeRate":0.044257},{"month":12,"riseRate":0.5,"avgChangeRate":0.126386}],"exchange":"NASDAQ","name":"Dynavax","nameEN":"Dynavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dynavax(DVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dynavax,DVAX,Dynavax股票,Dynavax股票老虎,Dynavax股票老虎国际,Dynavax行情,Dynavax股票行情,Dynavax股价,Dynavax股市,Dynavax股票价格,Dynavax股票交易,Dynavax股票购买,Dynavax股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dynavax(DVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dynavax(DVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction